ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Kristine Peregrino Lacuna, Shing M Lee, Liner Ge, Mihaela Druta, Anthony Paul Conley, Mary Louise Keohan, Mark Agulnik, Melissa Amber Burgess, Anna Weinberg Chalmers, Gina Z. D'Amato, Benjamin Powers, Mahesh Seetharam, Brittany L Siontis, Mia C. Weiss, Sminu (Sam) Bose, Tahir Sheikh, Richard Piekarz, Gary K. Schwartz, Matthew Ingham
Institutions: Columbia University Irving Medical Center, Columbia University, Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, City Of Hope National Medical Center, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Huntsman Cancer Institute, University of Miami Health System, Sylvester Comprehensive Cancer Center, University of Kansas Medical Center, Mayo Clinic in Arizona, Mayo Clinic, Washington University in St. Louis, National Institutes of Health, National Cancer Institute
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W4379345239